MENINGOCOCCAL ISOLATE SURVEILLANCE, AUSTRALIA, 1995

The National Neisseria Network

Abstract

In 1995 the National Neisseria Network examined 250 strains of Neisseria meningitidis isolated from invasive cases of meningococcal disease throughout Australia. The majority of isolates were either serogroup B (166, 66%) or serogroup C (69, 28%). There were only two serogroup A isolates. The proportion of isolates of serogroup B meningococci increased in 1995 from 54% in 1994. Most cases of invasive disease occurred in those less than four years of age (43%), with another peak in the 15 - 24 years age group (26%). Outcome data were available in 190 instances and there were 13 deaths recorded (7%). Penicillin susceptibility of isolates was little changed and minimal inhibitory concentrations (MICs) ranged between 0.002 and 0.5 mg/L. One hundred and fifty-five isolates were in the 'less susceptible' range (MIC 0.06 - 0.5 mg/L). Comm Dis Intell 1996;20:422-424.

Introduction

A national program for the examination of strains of Neisseria meningitidis from cases of invasive meningococcal disease was commenced in 1994 with the cooperation and participation of reference laboratories in each State and Territory.

This laboratory-based surveillance was designed to supplement data from existing clinical notification schemes by adding information on the serogroup of strains and antibiotic sensitivity data.

A report providing information gathered in the first year of the program was published in Communicable Diseases Intelligence.

The following report deals with the calendar year 1995.

Geographic distribution of serogroups

Two hundred and fifty invasive isolates of meningococci were examined in 1995 (Table 1). The serogroup was not

Table 1. Neisseria meningitidis isolates, 1995, by State or Territory and serogroup

<table>
<thead>
<tr>
<th>State or Territory</th>
<th>Serogroup</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B</td>
<td>C</td>
<td>A</td>
<td>Y</td>
<td>W135</td>
<td>NG</td>
</tr>
<tr>
<td>ACT</td>
<td>5</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>NSW</td>
<td>40</td>
<td>16</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>NT</td>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Qld</td>
<td>37</td>
<td>23</td>
<td>1</td>
<td></td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>SA</td>
<td>11</td>
<td>5</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tas</td>
<td>3</td>
<td>2</td>
<td></td>
<td></td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Vic</td>
<td>38</td>
<td>18</td>
<td></td>
<td></td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>WA</td>
<td>32</td>
<td>3</td>
<td></td>
<td></td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>TOTAL</td>
<td>166</td>
<td>69</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>5</td>
</tr>
</tbody>
</table>

1. NG = Non-groupable
2. Strains not available

Figure. Neisseria meningitidis isolates, 1995, by age group and sex

1. Corresponding author: John Tapsall, The Prince of Wales Hospital, High Street, Randwick, NSW 2031.
determined for five isolates. Serogroup B strains predominated in all States. There was a considerable reduction in the number of serogroup C isolates in New South Wales from 34 in 1994 to 16 in 1995. The marked predominance of serogroup B in Western Australia was again evident. Two isolates only of serogroup A were found, three of serogroup Y and two of serogroup W135.

**Age group and sex**

The age and sex distribution of patients infected with invasive isolates is shown in the Figure. The peak incidence of meningococcal disease occurred in those four years of age and under. There were 56 cases (22%) in those less than one year of age and 50 (20%) in the 1 - 4 years age group. Another peak was in the 15 - 24 years age group with 65 cases (26%). These findings showed a typical distribution of meningococcal disease.

**Site of isolation**

It is recognised that site of isolation of the organism is an inadequate classification as it probably underestimates the number of cases of meningitis where there was no lumbar puncture or where lumbar puncture was delayed and culture was sterile.

While other indicators may suggest meningitis in the absence of a positive cerebrospinal fluid (CSF) culture, and have been provided by respondents, in the interests of uniformity the above approach was used.

Within the limitations noted above, CSF isolates (either alone or with a blood culture isolate) totalled 116 (from 67 males and 49 females). This was fewer than the 133 blood culture isolates (from 69 males and 64 females) without culture of the organism from CSF.

**Outcome**

Outcome data (survived or died) were available for 190 of the 250 cases.

In cases of meningococcal meningitis, outcome data were available for 89 patients (Table 2). There were five deaths (6%).

In septicemic patients where information on outcome was available, 8 of 101 (8%) patients died (Table 3).

**Antibiotic susceptibility**

Considerable interest has been shown in the decrease in sensitivity of meningococci to penicillin in recent years. Strains with these characteristics have now been found in many parts of the world. Also, sporadic reports of β-lactamase producing meningococci continue to appear.

Other isolates have also been shown to be resistant to other antibiotics currently used either therapeutically or prophylactically in meningococcal disease. This program therefore undertakes routine surveillance of the antibiotic susceptibility of invasive isolates.

**Penicillin**

In the absence of accurate correlations between clinical response and in vitro sensitivity data in meningococcal disease, it is not possible to provide precise definitions of what constitutes a penicillin ‘resistant’ meningococcus.

Minimal inhibitory concentration (MIC) data are method dependent and not necessarily directly comparable when different techniques are used. This program uses the following parameters to define the various levels of penicillin susceptibility or resistance when determined by a standardised agar plate dilution technique:

- **Sensitive**: MIC ≤ 0.03 mg/L;
- **Less sensitive**: MIC 0.06 - 0.5 mg/L;
- **Relatively resistant**: MIC ≥ 1 mg/L;

Strains with MICs which place them in the category of ‘sensitive’ or ‘less sensitive’ would be considered to be amenable to penicillin therapy when used in currently recommended doses.

Using these criteria, 92 of the 247 (37%) invasive isolates tested were sensitive and 155 (63%) less sensitive to penicillin. The MICs ranged from 0.002 to 0.5 mg/L. This compares with 1994, where 102 of 214 (48%) isolates were fully sensitive and 112 (52%) less sensitive to penicillin with the MIC range 0.008 to 0.25 mg/L.

**Other antibiotics**

All 245 isolates tested were sensitive to ceftriaxone (and by extrapolation to other third-generation cephalosporins), rifampicin and ciprofloxacin. The latter two antibiotics are prophylactic, not therapeutic agents. A single isolate from New South Wales had a raised MIC to chloramphenicol.

Sulphonamide testing was not performed. Preliminary data indicated a significant amount of resistance to this agent in local isolates. This agent is no longer used in the treatment of this disease.

### Table 2. Outcome of cases with meningitis, by serogroup

<table>
<thead>
<tr>
<th>Serogroup</th>
<th>B</th>
<th>C</th>
<th>Y</th>
<th>U</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Survived</td>
<td>58</td>
<td>22</td>
<td>3</td>
<td>1</td>
<td>84</td>
</tr>
<tr>
<td>Died</td>
<td>4</td>
<td>1</td>
<td></td>
<td></td>
<td>5</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>62</td>
<td>23</td>
<td>3</td>
<td>1</td>
<td>89</td>
</tr>
</tbody>
</table>

1. Not serogrouped.

### Table 3. Outcome of cases with septicaemia, by serogroup

<table>
<thead>
<tr>
<th>Serogroup</th>
<th>B</th>
<th>C</th>
<th>W135</th>
<th>NG</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Survived</td>
<td>64</td>
<td>23</td>
<td>2</td>
<td>4</td>
<td>93</td>
</tr>
<tr>
<td>Died</td>
<td>5</td>
<td>3</td>
<td>2</td>
<td>4</td>
<td>8</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td>69</td>
<td>26</td>
<td>2</td>
<td>4</td>
<td>101</td>
</tr>
</tbody>
</table>

1. Non groupable
Acknowledgements

Isolates were received in the reference centres from many laboratories throughout Australia. The considerable time and effort involved in forwarding these strains is recognised and their efforts are greatly appreciated. These data could not have been provided without this assistance and the help of colleagues and public health personnel.

An initial grant for the National Neisseria Network was provided by the Commonwealth Department of Health and Family Services.

References


Participants in the Meningococcal Isolate Surveillance Programme

(to whom strains should be referred)

**ACT**

Dr J. Raby
Department of Microbiology
Royal Canberra Hospital South
PO Box 11
Woden ACT 2606

telephone (06) 244 2425

**New South Wales**

A/Prof. J. Tapsall
Microbiology Department
The Prince of Wales
Randwick NSW 2031

telephone (02) 9382 9079; fax (02) 9398 4275

or

A/Prof. Rosemary Munro
Department of Microbiology and Infectious Diseases
South West Area Pathology Service
Locked Mail Bag 90
Liverpool NSW 2179

telephone (02) 9828 5128; fax (02) 9828 5129

**Northern Territory**

Strains are referred from Alice Springs and Royal Darwin Hospitals to other centres

Contact Dr G. Lum
Royal Darwin Hospital

telephone (08) 89 228 091, fax (08) 89 228 843

**Queensland**

Mr J. Bates
Public Health Microbiology
Queensland Health Scientific Services
39 Kessels Road
Coopers Plains Qld 4108

telephone (07) 3274 9101, fax (07) 3274 9008

**South Australia**

Dr D. Hansman
Microbiology Department
Women’s and Children’s Hospital
72 King William Road
North Adelaide SA 5006

telephone (08) 8204 7326, fax (08) 8204 6051

**Tasmania**

Dr K. Ott
Department of Microbiology
Royal Hobart Hospital
GPO Box 1061L
Hobart Tas 7001

telephone (03) 62 388 410

**Victoria**

Dr J. Griffith or Dr M. Peel
Microbiological Diagnostic Unit
University of Melbourne
Parkville Vic 3052

telephone (03) 9344 5701

**Western Australia**

Mr C. Richardson (or in his absence Christina Farrer)
Department of Microbiology
Princess Margaret Hospital for Children
1 Thomas Street
Subiaco WA 6008

telephone (09) 340 8273, fax (09) 340 8273